Aadi Bioscience, Inc.

NasdaqCM AADI

Aadi Bioscience, Inc. Market Capitalization on January 14, 2025: USD 73.92 M

Aadi Bioscience, Inc. Market Capitalization is USD 73.92 M on January 14, 2025, a 83.38% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Aadi Bioscience, Inc. 52-week high Market Capitalization is USD 109.74 M on January 07, 2025, which is 48.46% above the current Market Capitalization.
Aadi Bioscience, Inc. 52-week low Market Capitalization is USD 32.46 M on July 02, 2024, which is -56.08% below the current Market Capitalization.
Aadi Bioscience, Inc. average Market Capitalization for the last 52 weeks is USD 48.41 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: AADI

Aadi Bioscience, Inc.

CEO	Mr. David J. Lennon Ph.D.
IPO Date	Feb. 16, 2018
Location	United States
Headquarters	17383 Sunset Boulevard
Employees	53
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key trends

Past 5 years